XIAP and prostate cancer: Antisense inhibitors of XIAP led to sensitization of castration-resistant prostate cancer cells to cisplatin and TNF-related apoptosis-inducing ligand (TRAIL) [40]; in PC3 prostate cancer xenografts, they caused sustained tumor regression in combination with docetaxel [41].